News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News TMX Group Thanksgiving Holiday Market Closures News TIPAK Marks Path to Leadership in Packaging Solutions Following Listing on SET News Chervon Names Daniel L. Abbott Director of Sales – Western U.S.A. News Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts News Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon Canada News Pelican Announces Appointment of Nino Di Teodoro to Its Board of Directors